NewLink Genetics (NLNK) PT Raised to $26 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NewLink Genetics (NLNK) PT Raised to $15 at Jefferies on Indoximod Data Expectations
March 1, 2017 7:48 AM ESTJefferies analyst Biren Amin raised its price target on NewLink Genetics (NASDAQ: NLNK) to $15.00 (from $12.00) while maintaining a Hold rating, as management guides to updated data from the melanoma trial of indox + PD-(L)1 inhibitor at AACR in April.
Amin comments, "NLNK plans to... More
NewLink Genetics (NLNK) Tops Q4 EPS by 16c
February 28, 2017 9:00 AM ESTNewLink Genetics (NASDAQ: NLNK) reported Q4 EPS of ($0.46), $0.16 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.46 million.
NewLink Genetics ended the year on December 31, 2016, with cash, cash equivalents, and certificates of deposit totaling... More
